Cph Group Ag Class A · SIX:CPHN
Cph Group Ag Class A — H1 2026 Earnings Presentation
36 slides from Cph Group Ag Class A's earnings presentation, Jul 21, 2026
Slide 1: A global leader in pharmaceutical packaging and attractive specialty chemicals niches
A global leader in pharmaceutical packaging and attractive specialty chemicals niches Half-Year Results Media, Analysts’ and Investors’ Conference 21 July 2026 1
Slide 2: Disclaimer
Disclaimer Investing in the shares of CPH Group AG involves risks. Prospective investors are urged to consult their investment advisors and tax advisors prior to investing in CPH Group AG shares. This document contains forward-looking statements which involve risks and uncertainties. These statement
Slide 3: Agenda
Agenda Highlights Business Financial Outlook and key figures development results H2 and mid-term Alois Waldburg-Zeil Alois Waldburg-Zeil Gerold Brütsch Alois Waldburg-Zeil CPH Group Media and Investors' Conference of 21 July 2026 3
Slide 4: Highlights
Highlights Perlen Packaging is Zeochem recorded a Transformation into Solid basis for growth, benefiting from stronger positive development in two well-positioned transformation and demand among molecular sieves for divisions is well stable cash flows pharmaceutical the energy and advanced with esta
Slide 5: Overview: Group with two well-positioned divisions
Overview Internationally active Group with two well-positioned divisions Perlen Packaging Zeochem 219 26 Key figures for 2025 in CHF millions 115 24 Sales EBITDA Sales EBITDA Differentiation through high customer benefit Focused growth strategy Differentiation through high customer benefit Worldwide
Slide 6: Key figures half-year 2026
Key figures half-year 2026 Positive developments in a challenging environment Sales EBITDA EBITDA margin in CHF millions in CHF millions in % 176 (HY25: 176) 28 (HY25: 30) 16 (HY25: 17) Net result Free cash flow Equity ratio in CHF millions in CHF millions in % 14 (HY25: 17) 13 (HY25: -2) 54 (2025:
Slide 7: Agenda
Agenda Highlights Business Financial Outlook and key figures development results H2 and mid-term Alois Waldburg-Zeil Alois Waldburg-Zeil Gerold Brütsch Alois Waldburg-Zeil CPH Group Media and Investors' Conference of 21 July 2026 7
Slide 8: Perlen Packaging
Perlen Packaging CPH Group Media and Investors' Conference of 21 July 2026 8
Slide 9: Business development Perlen Packaging – strategic milestones
Business development Perlen Packaging – strategic milestones o Strong demand from pharmaceutical customers amid supply chain uncertainties. o High order intake and full capacity utilization at Swiss and German production sites. Specialist in o Strengthening of market position and product portfolio t
Slide 10: Perlen Packaging – stabilization of sales and profitability
Business development Perlen Packaging – stabilization of sales and profitability 01.01.-30.06., in CHF millions 2026 2025 ± ±% Business development Sales 118.5 118.4 +0.1 +0.1% o Return to sales mix with increased share of higher-value EBITDA 18.2 17.8 +0.4 +2.0% blister packaging. EBITDA margin 15.
Slide 11: Zeochem
Zeochem CPH Group Media and Investors' Conference of 21 July 2026 11
Slide 12: Business development Zeochem – strategic milestones
Business development Zeochem – strategic milestones o Progress in strategic growth initiatives for deuterated compounds and chromatography gels. o SiliCycle advanced several promising projects in collaboration with pharmaceutical industry partners. o Further expanded synthesis Focus on high- capabil
Slide 13: Zeochem – slight moderation in growth momentum
Business development Zeochem – slight moderation in growth momentum 01.01.-30.06., in CHF millions 2026 2025 ± ±% Business development Sales 57.6 57.5 +0.1 +0.1% o Positive development in molecular sieves for the EBITDA 10.0 12.2 -2.2 -18.1% energy and chemicals sectors. EBITDA margin 17.3% 21.2% o
Slide 14: Agenda
Agenda Highlights Business Financial Outlook and key figures development results and Guidance Alois Waldburg-Zeil Alois Waldburg-Zeil Gerold Brütsch Alois Waldburg-Zeil CPH Group Media and Investors' Conference of 21 July 2026 14
Slide 15: Consolidated income statement I
Half-year 2026 Consolidated income statement I 1 Net sales 0.1% above prior-year period, 01.01.-30.06., in CHF millions 2026 % 2025 % ± ±% thereof +3.8% from acquisitions and -3.7% due Net sales 1 176.1 100.0 176.0 100.0 +0.1 +0.1% to FX. Other operating income 1.4 0.8 1.8 1.0 Organic growth flat at
Slide 16: Consolidated income statement II
Half-year 2026 Consolidated income statement II 1 Depreciation and amortization above prior 01.01.-30.06., in CHF millions 2026 % 2025 % ± ±% year as a consequence of acquisitions and EBITDA 28.3 16.1 30.2 17.2 -1.9 -6.3% prior-year capital expenditures. Depreciation expense 1 -9.3 -5.3 -8.3 -4.7 2
Slide 17: Consolidated balance sheet
Half-year 2026 Consolidated balance sheet 1 Increase in total assets by CHF 24.0 million in CHF millions 30.06.2026 % 31.12.2025 % ± ±% mainly driven by temporary seasonal increase Cash and cash equivalents 33.0 8.4 27.0 7.3 in trade receivables and cash. Trade receivables 72.9 18.6 56.5 15.3 2 Soli
Slide 18: Consolidated cash flow statement
Half-year 2026 Consolidated cash flow statement 1 Cash flow from operating activities above 01.01.-30.06., in CHF millions 2026 % 2025 % ± ±% prior-year period after prior-year period’s Net result 14.3 8.1 17.1 9.7 -2.8 -16.4% significant temporary increase in net working Non-cash items 8.7 5.0 8.4
Slide 19: Agenda
Agenda Highlights Business Financial Outlook and key figures development results H2 and mid-term Alois Waldburg-Zeil Alois Waldburg-Zeil Gerold Brütsch Alois Waldburg-Zeil CPH Group Media and Investors' Conference of 21 July 2026 19
Slide 20: Strong global megatrends
Outlook H2 and mid-term Strong global megatrends Megatrends Markets Applications Products Division Sales share1 Pharmaceutical Medicines packaging Respirators Health Pharmaceuticals Medical oxygen Molecular sieves 76% Chromatography gels API Deuterated compounds Natural gas/LNG Energy Industry Ethan
Slide 21: Remaining confident in the overall business outlook
Outlook H2 and mid-term Remaining confident in the overall business outlook Stronger market Perlen Packaging Zeochem aims to Strict cost discipline position and enhanced remains focused on capitalize on remains a key priority competitiveness operational excellence momentum in the across the Group. t
Slide 22: A solid basis for an attractive investment case
Outlook H2 and mid-term A solid basis for an attractive investment case Among the top 3 in Taking profit of Continuous Proven M&A and Strong balance attractive niche the global expansion of market integration skills to sheet and highly markets with above megatrends health position with a focus widen
Slide 23: Guidance 2026
Outlook H2 and mid-term Guidance 2026 CPH Group o Long-term megatrends of health and energy are intact. o Expanded product portfolio through recent acquisitions strengthens market position and competitiveness in both divisions. o Market conditions remain challenging. o Sales and EBITDA expected slig
Slide 24: Mid-term financial targets confirmed – higher payout ratio
Outlook Mid-term financial targets confirmed – higher payout ratio Growth Profitability Cash flow Financing Dividend Sales EBITDA Free cash Equity Payout increase margins flow margins ratio ratio 5-8% 16-18% 8-10% >50% 40-60% (previously: 25-50%) CPH Group Media and Investors' Conference of 21 July
Slide 25: CPH Group Media and Investors' Conference of 21 July 2026
CPH Group Media and Investors' Conference of 21 July 2026 25
Slide 26: Calendar and contacts
Calendar and contacts Calendar Analysts 29.09.2026 Baader Helvea CPH Group Investors‘ Meeting, Zurich Volker Bosse Contacts 13.–15.01.2027 Research Dynamics Alexandre Müller Alois Waldburg-Zeil Baader Helvea Swiss Equities CEO Conference, Bad Ragaz +41 41 455 87 67 Research Partners 18.02.2027 Eugen
Slide 27: Business locations worldwide
Business locations worldwide Consistent and ongoing internationalization over the last 15 years Müllheim 2007 Tököl 2025 2010 2025 Donghai Louisville Whippany Zvornik Louisville Whippany 2016 1979 2006 2018 1979 2006 Suzhou Müllheim Québec 2016 2007 2025 Perlen 1954 Perlen 1954 Anápolis Vadodara 201
Slide 28: Key figures CPH Group
Key figures CPH Group 1 76% of sales from health market Sales Sales by region Sales by application in CHF millions in CHF millions in CHF millions CAGR 5.9% 400 400 400 300 300 300 200 200 200 100 100 100 0 0 0 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 Europe The Ame
Slide 29: Perlen Packaging – a true global player
Perlen Packaging – a true global player Unique position in pharmaceutical packaging Whippany Müllheim Tököl Suzhou 2006 2007 2025 2016 Key figures 2025 Employees (in CHF millions) 784 Sales As of 2025 219 Global presence close to 5yrs CAGR 6.5% customers o 7 production sites EBITDA o 11 distributors
Slide 30: Perlen Packaging: Barrier effect
Perlen Packaging Pharmaceutical packaging with best protection for medicines Barrier effect Films for tablet blisters Up to 2x 50x better* better* Effectiveness of Effectiveness of water vapour oxygen barrier barrier Bottles and vials Up to 4x 100x 100x Up to 4x better* better* better* better* Effec
Slide 31: Perlen Packaging: No. 1 worldwide in highest barrier blister
Perlen Packaging No. 1 worldwide in highest barrier blister1 Global pharmaceutical market Largest markets Global pharmaceutical Global pharmaceutical outlook 20262 blister market: bottle market: o 1: USA CHF 2 billion 1 CHF 8 billion 1 o 2: China Growth: Growth: Strategic directions o 3: Germany 3-6
Slide 32: Zeochem – top global niche player in specialty chemicals
Zeochem – top global niche player in specialty chemicals Leading market position backed by global megatrends Louisville Québec Zvornik Donghai 1979 2025 2018 2016 Key figures 2025 Employees (in CHF millions) 452 Sales As of 2025 115 Global presence close to 5yrs CAGR 4.8% customers o 6 production si
Slide 33: Zeochem: Product portfolio
Zeochem Product portfolio improves quality of life and enables energy transition Molecular Chromatography Deuterated sieves gels products o Molecular sieves are used in o Highly porous gels for molecular o Hydrogen atom in different removing unwanted molecules and separation for use in the molecules
Slide 34: Zeochem: Molecular sieves for industrial applications
Zeochem Moleculars sieves for industrial applications Market overview Industries Global fragmented market o Pharmaceuticals with growth o Electronics o Petrochemistry 2-3% p.a. 1 o Manufacturing industries (glass, steel) o Automotive industry o Construction industry Strategic directions Segment mole
Slide 35: Zeochem: Chromatography gels for pharmaceuticals
Zeochem Chromatography gels for pharmaceuticals Market overview Industries Global fragmented market o Pharmaceuticals with growth o Biopharmaceuticals o Academia & Universities 5-10% p.a. 1 o Food & Beverage industry o Cosmetics Strategic directions Segment chromatography gels o Develop potential of
Slide 36: Zeochem: Deuterated compounds for pharmaceuticals and electronics
Zeochem Deuterated compounds for pharmaceuticals and electronics Market overview Industries Global fragmented market with o Pharmaceuticals growth o Electronics o Basic research 10% p.a. 1 Strategic directions Segment deuterated compounds o Focus on innovation CHF 100-150 million 1 o Increased produ